A progressive policy group says prescription drug price control advocates at the federal and state level should start prepping now for the possibility that a years-long conservative effort to reshape the federal government could undo Democrats’ flagship Medicare prescription drug reforms should Republicans win in November, warning at least 18.5 million beneficiaries potentially could lose new cost-savings on their medications.